AIDS and Behavior

, Volume 17, Issue 1, pp 1–4 | Cite as

Is the US AIDS Drug Assistance Program Cost-effective?

  • Steven D. Pinkerton
  • Jennifer Kibicho
  • Carol L. Galletly
Original Paper

Abstract

Each year, the US AIDS drug assistance program (ADAP) provides access to prescription drugs—including antiretrovirals—to more than 110,000 persons living with HIV (PLWH) who lack adequate medical insurance. PLWH on effective antiretroviral therapy live longer lives, with enhanced quality of life, and are less likely to transmit HIV to others. There are thus significant benefits associated with the ADAP program. But there also are substantial costs. A mathematical model was used to assess the cost-effectiveness of the US ADAP program. Findings indicate that by providing antiretrovirals to underinsured persons, the ADAP program prevented 3,191 secondary infections and saved 24,922 quality-adjusted life years in 2008. The net cost per quality-adjusted life year saved was $11,955, which suggests that the ADAP program is cost-effective by conventional standards.

Keywords

AIDS drug assistance program Antiretroviral therapy Cost-effectiveness 

References

  1. 1.
    Kates J, Penner MC, Crutsinger-Perry B, Leggoe AW, Singleton N. National ADAP monitoring project: annual report. The Henry J. Kaiser Family Foundation (KFF) and The National Alliance of State and Territorial AIDS Directors (NASTAD) (2005).Google Scholar
  2. 2.
    Carbaugh AL, Kates J, Crutsinger-Perry B, Ginsburg B, Penner MC. National ADAP monitoring project: annual report. The Henry J. Kaiser Family Foundation (KFF) and The National Alliance of State and Territorial AIDS Directors (NASTAD) (2009).Google Scholar
  3. 3.
    Kaiser Family Foundation. AIDS drug assistance programs (ADAPs). 2009 Fact Sheet #1584. Accessed 2 July 2011 http://www.kff.org/hivaids/upload/1584_10.pdf.
  4. 4.
    Johri M, Paltiel D, Goldie SJ, Freedberg KA. State AIDS drug assistance programs: equity and efficiency in an era of rapidly changing treatment standards. Med Care. 2002;40:429–41.PubMedCrossRefGoogle Scholar
  5. 5.
    Chen LF, Hoy J, Lewin SR. Ten years of highly active antiretroviral therapy for HIV infection Med J Aust. 2007;186:146–51.Google Scholar
  6. 6.
    The Strategies for Management of Antiretroviral Therapy (SMART) Study Group. CD4+ count-guided interruption of antiretroviral treatment. NEJM. 2006;355:2283–96.CrossRefGoogle Scholar
  7. 7.
    Burman, WJ, Grund B, Roediger MP, Friedland G, Darbyshire J, Wu AW, for the SMART Study Group. The impact of episodic CD4 cell count–guided antiretroviral therapy on quality of life. J Acquir Immune Defic Synd 2008;47:185–193.Google Scholar
  8. 8.
    Attia S, Egger M, Muller M, Zwahlen M, Low N. Sexual transmission of HIV according to viral load and antiretroviral therapy: systematic review and meta-analysis. AIDS. 2009;23:1397–404.PubMedCrossRefGoogle Scholar
  9. 9.
    De Cock KM, Crowley SP, Lo Y-R, Granich RM, Williams BG. Preventing HIV transmission with antiretrovirals. Bull World Health Organ. 2009;87:488–9.PubMedCrossRefGoogle Scholar
  10. 10.
    Pinkerton SD. HIV transmission rate modeling: a primer, review, and extension. AIDS Behav. 2011;16(4):791–6. doi:10.1007/s10461-011-0042-8.CrossRefGoogle Scholar
  11. 11.
    Schackman BR, Gebo KA, Walensky RP, Losina F, Muccio T, et al. The lifetime cost of current human immunodeficiency virus care in the United States. Med Care. 2006;44:990–7.PubMedCrossRefGoogle Scholar
  12. 12.
    Farnham PG, Sansom SL, Hutchinson AB. How much should we pay for a new HIV diagnosis? A mathematical model of HIV screening in US clinical settings. Med Decis Making 2012; 32(3):459–69. http://mdm.sagepub.com/content/early/2012/01/03/0272989X11431609.full.pdf.
  13. 13.
    Tengs TO, Lin TH. A meta-analysis of utility estimates for HIV/AIDS. Med Decis Making. 2002;22:475–81.PubMedCrossRefGoogle Scholar
  14. 14.
    Mannheimer SB, Matts J, Telzak E, Chesney M, Child C, Wu AW, et al. Quality of life in HIV-infected individuals receiving antiretroviral therapy is related to adherence. AIDS Care. 2005;17:10–22.PubMedCrossRefGoogle Scholar
  15. 15.
    Centers for Disease Control and Prevention. Vital signs: HIV prevention through care and treatment, United States. MMWR. 2011;60:1618–23.Google Scholar
  16. 16.
    Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, et al. Prevention of HIV-1 infection with early antiretroviral therapy. NEJM. 2011;365:493–505.PubMedCrossRefGoogle Scholar
  17. 17.
    Marks G, Crepaz N, Janssen RS. Estimating sexual transmission of HIV from persons aware and unaware that they are infected with the virus in the USA. AIDS. 2006;20:1447–50.PubMedCrossRefGoogle Scholar
  18. 18.
    Quinn TC, Wawer MJ, Sewankambo N, Serwadda D, Li C, Wabwire-Mangen F, et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. NEJM. 2000;342:921–9.PubMedCrossRefGoogle Scholar
  19. 19.
    Laufer FN. Thresholds in cost-effectiveness analysis—more of the story. Value in Health. 2005;8:86–7.PubMedCrossRefGoogle Scholar
  20. 20.
    Laupacis A, Feeny D, Detsky AS, Tugwell PX. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. CMAJ. 1992;146:473–81.PubMedGoogle Scholar
  21. 21.
    Schrappe M, Lauterbach K. Systematic review on the cost-effectiveness of public health interventions for HIV prevention in industrialized countries. AIDS 1998;12 (suppl A):S231–S238.Google Scholar
  22. 22.
    Tengs TO, Adams ME, Pliskin JS, Safran DG, Siegel JE, Weinstein MC, et al. Five-hundred life-saving interventions and their cost-effectiveness. Risk Anal. 1995;15:369–90.PubMedCrossRefGoogle Scholar
  23. 23.
    Prejean J, Song R, Hermandez A, Ziebell R, Green T, Walker F, et al. Estimated HIV incidence in the United States, 2006–2009. PLoS ONE. 2011;6:e17502. doi:10.1371/journal.pone.0017502.PubMedCrossRefGoogle Scholar
  24. 24.
    Kaiser Family Foundation. AIDS drug assistance programs (ADAPs) with waiting lists or other cost-containment strategies, as of May 2011. Accessed 15 June 2011http://www.statehealthfacts.org/comparemaptable.jsp?ind=552&cat:11&sub=204&yr=1&typ=5.
  25. 25.
    Centers for Disease Control and Prevention. HIV surveillance—United States, 1981–2008. MMWR. 2011;60:689–93.Google Scholar
  26. 26.
    Pinkerton SD. How many sexually-acquired HIV infections in the US are due to acute-phase HIV transmission? AIDS. 2007;21:1625–9.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2012

Authors and Affiliations

  • Steven D. Pinkerton
    • 1
  • Jennifer Kibicho
    • 1
  • Carol L. Galletly
    • 1
  1. 1.Center for AIDS Intervention Research, Department of Psychiatry and Behavioral MedicineMedical College of WisconsinMilwaukeeUSA

Personalised recommendations